Akebia Therapeutics Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Akebia Therapeutics (AKBA) PT Lowered to $18 at Needham & Company
August 9, 2018 1:40 PM EDTNeedham & Company lowered its price target on Akebia Therapeutics (NASDAQ: AKBA) to $18.00 (from $20.00) while maintaining a Buy rating.
Analsyt Chad Messer notes vadadustat pivotal readouts were pushed out. "We continue to expect that INNO2VATE will be fully enrolled by YE:18; however,... More
